Literature DB >> 28065273

Screening and Characterization Strategies for Nanobodies Targeting Membrane Proteins.

S Veugelen1, M Dewilde1, B De Strooper2, L Chávez-Gutiérrez3.   

Abstract

The study of membrane protein function and structure requires their successful detection, expression, solubilization, and/or reconstitution, which poses a challenging task and relies on the availability of suitable tools. Several research groups have successfully applied Nanobodies in the purification, as well as the functional and structural characterization of membrane proteins. Nanobodies are small, single-chain antibody fragments originating from camelids presenting on average a longer CDR3 which enables them to bind in cavities and clefts (such as active and allosteric sites). Notably, Nanobodies generally bind conformational epitopes making them very interesting tools to stabilize, dissect, and characterize specific protein conformations. In the clinic, several Nanobodies are under evaluation either as potential drug candidates or as diagnostic tools. In recent years, we have successfully generated high-affinity, conformation-sensitive anti-γ-secretase Nanobodies. γ-Secretase is a multimeric membrane protease involved in processing of the amyloid precursor protein with high clinical relevance as mutations in its catalytic subunit (Presenilin) cause early-onset Alzheimer's disease. Advancing our knowledge on the mechanisms governing γ-secretase intramembrane proteolysis through various strategies may lead to novel therapeutic avenues for Alzheimer's disease. In this chapter, we present the strategies we have developed and applied for the screening and characterization of anti-γ-secretase Nanobodies. These protocols could be of help in the generation of Nanobodies targeting other membrane proteins.
© 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AlphaScreen; Alzheimer's disease; Biopanning; Membrane; Nanobody; γ-Secretase

Mesh:

Substances:

Year:  2016        PMID: 28065273     DOI: 10.1016/bs.mie.2016.10.029

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  5 in total

Review 1.  Exploring cellular biochemistry with nanobodies.

Authors:  Ross W Cheloha; Thibault J Harmand; Charlotte Wijne; Thomas U Schwartz; Hidde L Ploegh
Journal:  J Biol Chem       Date:  2020-08-31       Impact factor: 5.157

Review 2.  The Role of microRNAs in Alzheimer's Disease and Their Therapeutic Potentials.

Authors:  Munvar Miya Shaik; Ian A Tamargo; Murtala B Abubakar; Mohammad A Kamal; Nigel H Greig; Siew Hua Gan
Journal:  Genes (Basel)       Date:  2018-03-21       Impact factor: 4.096

3.  Development of specific nanobodies (VHH) for CD19 immuno-targeting of human B-lymphocytes.

Authors:  Seyed Reza Banihashemi; Ahmad Zavaran Hosseini; Fatemeh Rahbarizadeh; Davoud Ahmadvand
Journal:  Iran J Basic Med Sci       Date:  2018-05       Impact factor: 2.699

4.  VHH antibody targeting the chemokine receptor CX3CR1 inhibits progression of atherosclerosis.

Authors:  Sarah Low; Haixia Wu; Kavita Jerath; Annette Tibolla; Birgit Fogal; Rebecca Conrad; Margit MacDougall; Steven Kerr; Valentina Berger; Rajvee Dave; Jorge Villalona; Lynn Pantages; Jennifer Ahlberg; Hua Li; Diane Van Hoorick; Cedric Ververken; John Broadwater; Alisa Waterman; Sanjaya Singh; Rachel Kroe-Barrett
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

5.  A cDNA Immunization Strategy to Generate Nanobodies against Membrane Proteins in Native Conformation.

Authors:  Thomas Eden; Stephan Menzel; Janusz Wesolowski; Philine Bergmann; Marion Nissen; Gudrun Dubberke; Fabienne Seyfried; Birte Albrecht; Friedrich Haag; Friedrich Koch-Nolte
Journal:  Front Immunol       Date:  2018-01-23       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.